{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:58:14Z","timestamp":1769731094378,"version":"3.49.0"},"reference-count":47,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The optimal approach to treat invasive fungal disease (<jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content>) caused by more than one fungal species is unknown. We documented the efficacy and safety of isavuconazole for treatment of <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content>s caused by more than one fungal species. <jats:styled-content style=\"fixed-case\">VITAL<\/jats:styled-content> was a single\u2010arm, international, open\u2010label study evaluating the efficacy and safety of isavuconazole (200\u00a0mg orally or intravenously every 8\u00a0hours for 48\u00a0hours, then once daily) for treatment of rare <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content>s. The primary outcome was the overall response at Day 42; key secondary outcomes were overall responses at Day 84 and end of treatment (<jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>), mortality at Days 42 and 84, and safety. This analysis includes patients with <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content> caused by multiple fungal species. Fifteen patients were included in this analysis (including <jats:italic>Aspergillus<\/jats:italic> spp., n\u00a0=\u00a011; without <jats:italic>Aspergillus<\/jats:italic> spp., n\u00a0=\u00a04); median treatment duration was 97 days [range, 6\u2010544] days). Overall treatment success was observed in 2\/15 patients (13.3%) at Days 42 and 84, and 2\/14 (14.3%) at <jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>. All\u2010cause mortality was 2\/15 (13.3%) at Day 42 and 4\/15 (26.7%) at Day 84. All patients had \u22651 treatment\u2010emergent adverse event (<jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>); 12 patients (80.0%) had serious <jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s; <jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s led to discontinuation of isavuconazole in two patients (13.3%). Isavuconazole may be useful to treat some <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content>s caused by multiple fungal species.<\/jats:p>","DOI":"10.1111\/myc.12777","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T08:12:01Z","timestamp":1522743121000},"page":"485-497","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M.","family":"Marty","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Brigham and Women's Hospital  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Trials Centre Cologne ZKS K\u00f6ln, and Cologne Excellence Cluster on Cellular Stress Responses in Aging\u2010Associated Diseases (CECAD) University of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Mullane","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Section of Infectious Diseases University of Chicago  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Ostrosky\u2010Zeichner","sequence":"additional","affiliation":[{"name":"University of Texas Medical School at Houston and Memorial Hermann Texas Medical Center University of Texas  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rochelle M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Croos\u2010Dabrera","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyang","family":"Lu","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lademacher","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Oren","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Rambam Health Care Campus  Haifa Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Hortense","family":"Schmitt\u2010Hoffmann","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Giladi","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit Tel Aviv Sourasky Medical Center and The Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit Sheba Medical Center Tel Hashomer, and The Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Infectious Diseases Duke University  Durham NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0247"},{"key":"e_1_2_6_4_1","first-page":"954186","article-title":"Mixed fungal infection (Aspergillus, Mucor, and Candida) of severe hand injury","volume":"2014","author":"Obradovic\u2010Tomasev M","year":"2014","journal-title":"Case Rep Infect Dis"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-013-9706-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2010.01406.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05379.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2000.00537.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.5.1532-1535.1999"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.1991.tb01542.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2015.10.001"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00295-15"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-012-0022-4"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155208094123"},{"key":"e_1_2_6_15_1","first-page":"83","article-title":"Unsuccessful therapy of combined mycotic infection in a severely burned patient: a case study","volume":"51","author":"Lipovy B","year":"2009","journal-title":"Acta Chir Plast"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.017"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-5082-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.10.013"},{"key":"e_1_2_6_19_1","first-page":"2630","article-title":"Invasive fungal infection in Ramathibodi Hospital: a ten\u2010year autopsy review","volume":"90","author":"Larbcharoensub N","year":"2007","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12344"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0456"},{"key":"e_1_2_6_22_1","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley MA","year":"2016","journal-title":"Infect Drug Resist"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw305"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12778"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12769"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_6_29_1","volume-title":"Document M27\u2010A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Edition","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"e_1_2_6_30_1","volume-title":"Document M38\u2010A2. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Second Edition","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"e_1_2_6_31_1","unstructured":"Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing.EUCAST Definitive Document EDef 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds.2008."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01935.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817947.ch17"},{"key":"e_1_2_6_34_1","unstructured":"CornelyOA Ostrosky\u2010ZeichnerL RahavG et\u00a0al.Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting; Sept 5\u20109 2014 2014;Washington DC USA."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01141-13"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03779-14"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01111-13"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki399"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01919-15"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05910-11"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01655-09"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.04.008"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12234"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00637-15"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix210"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12228"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T23:27:16Z","timestamp":1695425236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/myc.12777"],"URL":"https:\/\/doi.org\/10.1111\/myc.12777","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"2018-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}